WO2013187552A1 - Composition anti-inflammatoire comprenant un alloféron et composition cosmétique la comprenant - Google Patents

Composition anti-inflammatoire comprenant un alloféron et composition cosmétique la comprenant Download PDF

Info

Publication number
WO2013187552A1
WO2013187552A1 PCT/KR2012/005530 KR2012005530W WO2013187552A1 WO 2013187552 A1 WO2013187552 A1 WO 2013187552A1 KR 2012005530 W KR2012005530 W KR 2012005530W WO 2013187552 A1 WO2013187552 A1 WO 2013187552A1
Authority
WO
WIPO (PCT)
Prior art keywords
gly
ser
val
ala
ile
Prior art date
Application number
PCT/KR2012/005530
Other languages
English (en)
Korean (ko)
Inventor
김수인
이왕재
Original Assignee
(주)알로텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)알로텍 filed Critical (주)알로텍
Publication of WO2013187552A1 publication Critical patent/WO2013187552A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention is directed to an anti-inflammatory pharmaceutical composition
  • alleron which is useful for the treatment of skin diseases caused by inflammation caused by inflammation such as burns or abrasions, allergens such as bacteria, fungi, pollen, and the like, and various inflammations caused by ultraviolet rays.
  • a cosmetic composition for promoting recovery or regeneration of damaged skin.
  • alleronone is isolated from the blow fly Calliphora vicina challenged by bacteria. It became. Both types of alleronone, alleronone 1 and 2, are known to have 13 and 12 amino acids, respectively (S. Chernysh, SI Kim, G. Bekker, VA Pleskach, NA Filatova, VB Anilin, VG Platonom, P. Bulet, Proc. Natl. Acad. Sci.
  • Alloferon 1 is known to have the sequence of HGVSGHGQHGVHG (SEQ ID NO: 1) and alloferon 2 has the sequence of GVSGHGQHGVHG (SEQ ID NO: 2).
  • Alloferon stimulated rat and human lymphocytes in in vivo experiments and induced interferon (IFN) synthesis in mice in vivo.
  • Alloferones have been known to enhance the synthesis of interferons when infected with a virus (SI Chernysh, SI Kim, GP Bekker, NB Makhaldiani, G. Hoffmann, F. Buhle, Patent No 2172322, Byull. Izobret. 23 (2001) no 23 .; SI Kim, SI Chernysh, GP Bekker, N. Makhaldiani, J. Hoffman, P. Bulet, United States, Patent Application Publication, US 2002-0151679 A1, Oct. 17, 2002. SI Kim, SI Chernysh, GP Bekker, N. Makhaldiani, J. Hoffman, P.
  • Patent application 10-2000-0082812 discloses an immunomodulator comprising alloperone. Although the antiviral and immunomodulatory effects of alloperon have been reported, there have been no reports of the anti-inflammatory effect of alloperon or the promotion of repair or regeneration of damaged skin.
  • the present inventors have completed the present invention by discovering that alloperon has an effect such as anti-inflammatory effect, recovery of damaged skin, and regeneration.
  • a first form of the invention provides a pharmaceutical composition comprising alloferon.
  • alloferon is a peptide or a pharmaceutically acceptable salt or ether thereof having up to 30 amino acid residues having the following general structure (1) and exhibiting anti-inflammatory activity:
  • X 1 is absent or represents at least one amino acid residue
  • X 2 represents a peptide bond or at least one amino acid residue
  • X 3 is absent or represents at least one amino acid residue.
  • X 1 contains nothing, His-Gly-Val-Ser-Gly-, Gly-Val-Ser-Gly-, Val-Ser-Gly-, Ser-Gly-, Pro-Ser-Leu-Thr -Gly-, Phe-Ile-Val-Ser-Ala-, Thr-, Leu-Ala-Ser-Leu-, Cys-Val-Val-Thr-Gly-, Ile-Ser-Gly-, Cys-Gly-, Peptides selected from the group consisting of Ile-Val-Ala-Arg-Ile-, Phe-Gly-, His-Gly-Asp-Ser-Gly-, Ser-Gly- and Tyr-Ala-Met-Ser-Gly- ego;
  • X 2 is a peptide bond or -Gln-, -Phe-, -Asp-, -Ser-, -Asn-, -Ala-,-Gln-Asn-, -Ala-Val- and -Ser-Asp-Gly- A peptide selected from the group consisting of; And,
  • X 3 contains nothing, -His-Gly, -His, -Tyr-Asp, -Phe-Val, -Pro, -Gln-His-Gly, -Leu-Ala, -Asp, -Pro-Leu,- A peptide selected from the group consisting of Met and -Phe-Ile is shown.
  • the dosage of the anti-inflammatory pharmaceutical composition comprising the alleronone used to achieve the therapeutic effect according to the invention, as well as the particular compound, the method of administration, the subject to be treated, and the disease to be treated is usually 0.001 mg / Kg to 400 mg. / Kg, may be administered once or several times a day, the dosage can be adjusted in various ways depending on the patient's weight, age, sex, health status, diet, time of administration, administration method, excretion rate and the severity of the disease
  • the method of administration may be administered in oral or parenteral administration (eg, intravenous subcutaneous, intraperitoneal, topical or visual route), in the form of pills, capsules, powders, solutions, and anal suppositories. More preferred.
  • Tablets according to the invention may be administered to a patient in any form or manner in which bioavailability is in an effective amount, ie, parenterally, and is suitable for the nature of the disease state to be treated, the stage of the disease, and other relevant circumstances.
  • the dosage form or mode may be readily selected and the composition according to the invention may comprise one or more pharmaceutically acceptable excipients, wherein the proportions and properties of such excipients may depend on the solubility and chemical properties of the selected tablet, It is determined by the route of administration and standard drug practice.
  • compositions according to the invention may comprise a therapeutically effective amount of the above-mentioned active ingredient as an essential ingredient together with one or more pharmaceutically acceptable excipients.
  • Excipient materials can be solid or semisolid materials that can function as a vehicle or medium of the active ingredient, and suitable excipients are well known in the art.
  • a second aspect of the present invention provides a cosmetic composition comprising the alloperone compound and a physiologically acceptable cosmetic base.
  • the cosmetic composition of this invention contains an alleronone compound at 0.001-30 weight% with respect to the whole composition.
  • the content range is considered to achieve the anti-inflammatory effect of the alleronone compound, when the content is less than 0.001% by weight, the anti-inflammatory effect is insignificant, and when the content exceeds 30% by weight is insignificant This is considered.
  • the cosmetic composition of the alloperone of the present invention is not particularly limited in its formulation, it may include a skin cosmetic compounding components commonly used in the art to which the present invention belongs depending on the formulation to be prepared.
  • the cosmetic composition comprising the alleronone of the present invention can be prepared in a formulation such as lotion (skin), milky lotion, cream, pack, essence, etc., in addition to the oil, water, surfactants, moisturizers depending on the formulation to be prepared Lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances and the like can be selected and added in appropriate amounts.
  • a cosmetic it is preferable to be directly applied to the skin or administered by a method such as spray (spray).
  • the pharmaceutical composition and the cosmetic composition comprising alloperone according to the present invention have an anti-inflammatory effect, and in particular, the occurrence of various inflammations caused by allergens such as bacteria, fungi, pollen, burns and abrasions, including ultraviolet irradiation. It is a composition that not only suppresses, but also prevents deformation and damage of the skin, as well as promotes recovery and regeneration of damaged skin.
  • HaCaT cells were exposed to UVB (100 J / m 2 ) and treated with 4 ⁇ g / ml alloferone and 5 ⁇ M SB203580 for 24 hours. The culture supernatant was collected and the production change of IL-6 was measured by ELISA.
  • HaCaT cells were exposed to UVB (100 J / m 2 ) and treated with 4 ⁇ g / ml of alleronone at the indicated experimental times (30 minutes, 60 minutes and 120 minutes). Cells were lysed using Triton X-100 lysis buffer. Changes in p-p38MAPK expression were measured using Western blot analysis. The density of each band was measured using Densitomitri and compared with that of p38 MAPK. Values expressed p-p38 MAPK as a ratio to p38 MAPK.
  • Figure 4 shows the effect of local treatment of alleronone on skin epidermal hyperplasia mediated by UV irradiation in HR-1 hairless mouse skin.
  • Groups of mice were not exposed (control) (a), exposed to UVB (100 J / m 2 ) (b), or exposed to UVB (100 J / m 2 ) and then alleronone (1000 ng / l ml PBS / Mice) immediately (c) or alloperon (1000 ng / l ml PBS / mouse) locally to the dorsal skin (d).
  • alleronone 1000 ng / l ml PBS / Mice
  • alloperon 1000 ng / l ml PBS / mouse
  • mice 5 shows the effect of local treatment of alloperon on UVB-induced IL-6 production in HR-1 hairless mouse skin.
  • Groups of mice were not exposed (control) (a), exposed to UVB (100 J / m 2 ) (b), or exposed to UVB (100 J / m 2 ) and then alleronone (1000 ng / l ml PBS / Mice) immediately (c) or alloperon (1000 ng / l ml PBS / mouse) locally to the dorsal skin (d).
  • alleronone 1000 ng / l ml PBS / Mice
  • alloperon 1000 ng / l ml PBS / mouse
  • RNase Protection Assay was used to identify changes in the expression of mRNA transcripts of various proinflammatory cytokines. MRNA expression of proinflammatory cytokines such as IL-1 ⁇ , IL-1 ⁇ , IL-6 and IL-18 was significantly increased by irradiation with ultraviolet light. Interestingly, the expression of these increased mRNAs was significantly reduced by pretreatment of alloperon 1 (FIG. 2A).
  • the concentrations of IL-1 ⁇ , IL-1 ⁇ , IL-6 and IL-18 were measured in HaCat cells irradiated with ELISA after reaction in the presence or absence of alleronone.
  • production of IL-1 ⁇ , IL-1 ⁇ , IL-6 and IL-18 in UV treated keratinocytes was increased, and the benefits are consistent with previously published data (Schwarz T and Luger TA, 1989).
  • alleronone 1 reduced cytokine production of UV-induced IL-1 ⁇ , IL-1 ⁇ , IL-6 and IL-18 to significant levels (Fig. 2b to 2e).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition anti-inflammatoire comprenant un alloféron, et un produit cosmétique la comprenant, l'alloféron ayant un effet de lutte contre l'inflammation ainsi qu'un effet antiviral et un effet d'immunomodulation. En particulier, la composition de la présente invention est efficace contre des allergènes tels que virus, eumycètes et pollen ainsi que contre diverses inflammations cutanées provoquées par des brûlures ou des écorchures, la composition ayant donc comme effets remarquables la capacité de non seulement empêcher une déformation et un endommagement de la peau mais également de réparer la peau endommagée ou de favoriser la régénération de la peau endommagée. La composition cosmétique ou le produit cosmétique selon la présente invention a comme effet de prévenir une inflammation de la peau et de protéger la peau contre divers facteurs induisant une inflammation tels que les rayons ultraviolets.
PCT/KR2012/005530 2012-06-11 2012-07-12 Composition anti-inflammatoire comprenant un alloféron et composition cosmétique la comprenant WO2013187552A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2012-0062301 2012-06-11
KR1020120062301A KR20130138590A (ko) 2012-06-11 2012-06-11 알로페론을 포함하는 항염증 약학적 조성물 및 화장료 조성물

Publications (1)

Publication Number Publication Date
WO2013187552A1 true WO2013187552A1 (fr) 2013-12-19

Family

ID=49758356

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/005530 WO2013187552A1 (fr) 2012-06-11 2012-07-12 Composition anti-inflammatoire comprenant un alloféron et composition cosmétique la comprenant

Country Status (2)

Country Link
KR (1) KR20130138590A (fr)
WO (1) WO2013187552A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102257913B1 (ko) * 2018-07-17 2021-05-28 주식회사 에이티파머 알로페론을 포함하는 폐섬유증 치료용 조성물
KR102253714B1 (ko) * 2020-12-07 2021-05-27 유광진 알로페론 판토텐산 복합체를 유효성분으로 함유하는 미백용 또는 주름개선용 조성물
KR102253715B1 (ko) * 2020-12-07 2021-05-27 유광진 면역활성을 유도하는 장기 안정성을 가지는 알로페론 복합체
WO2023229443A1 (fr) * 2022-05-27 2023-11-30 주식회사 진큐어 Nouveau peptide et son utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100394864B1 (ko) * 1999-12-27 2003-08-19 주식회사 엔토팜 알로페론-면역조절펩티드
WO2005068491A1 (fr) * 2004-01-15 2005-07-28 Sergey Ivanovich Chernysh Peptides antitumoraux et antiviraux
WO2008007997A1 (fr) * 2006-07-13 2008-01-17 Society With Limited Liability Allopharm (Allopharm Ltd) Agent anti-inflammatoire à usage externe
KR20100106791A (ko) * 2009-03-24 2010-10-04 주식회사 엔토팜 히스티딘을 포함하는 펩타이드 유사체 및 항바이러스제 또는 항암제로서의 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100394864B1 (ko) * 1999-12-27 2003-08-19 주식회사 엔토팜 알로페론-면역조절펩티드
WO2005068491A1 (fr) * 2004-01-15 2005-07-28 Sergey Ivanovich Chernysh Peptides antitumoraux et antiviraux
WO2008007997A1 (fr) * 2006-07-13 2008-01-17 Society With Limited Liability Allopharm (Allopharm Ltd) Agent anti-inflammatoire à usage externe
KR20100106791A (ko) * 2009-03-24 2010-10-04 주식회사 엔토팜 히스티딘을 포함하는 펩타이드 유사체 및 항바이러스제 또는 항암제로서의 이의 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHERNYSH, SERGEY ET AL.: "Antiviral and antitumor peptides from insects", PNAS, vol. 99, no. 20, 2002, pages 12628 - 12632, XP002455077 *

Also Published As

Publication number Publication date
KR20130138590A (ko) 2013-12-19

Similar Documents

Publication Publication Date Title
KR101699572B1 (ko) 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물
US7687083B2 (en) Pharmaceutical compositions comprising old man's beard (Usnea barbata) and St. John's wort (Hypericum perforatum) and their use
WO2013187552A1 (fr) Composition anti-inflammatoire comprenant un alloféron et composition cosmétique la comprenant
JP6603216B2 (ja) 殺腫瘍性および抗菌性の組成物ならびに方法
EP2854784B1 (fr) Méthode de traitement de maladies inflammatoires de la peau
EP2922573B1 (fr) Composition pharmaceutique utilisée pour réduire les dommages provoqués par les radicaux libres
WO2019151744A1 (fr) Nanovésicules dérivées de cellules souches adultes et leur utilisation pour une thérapie ciblée
EP3583934B1 (fr) Agent à effet biocide
WO2019004738A2 (fr) Utilisation d'une composition comprenant un exosome dérivé de cellules souches adipeuses en tant que principe actif pour atténuer la dermatite
EP2623111A2 (fr) Peptides de venin de scorpion rhopalurus junceus et composition pharmaceutique
KR101478520B1 (ko) 피부 안전성이 향상된 캡사이신-펩타이드 및 이를 이용한 피부 외용제 조성물
DE112015004182T5 (de) Antimykotische Zusammensetzung umfassend antimykotisches Peptid und Terpenalkohol
EP2670420B1 (fr) Agent antiviral contenant des lectines du gui recombinantes
AU2009258034B2 (en) Improved beta thymosin fragments
KR20220033450A (ko) 니클로사마이드를 포함하는 항인플루엔자 바이러스용 조성물
EP3583103B1 (fr) Extraits de plantes enrichis avec dérivés d'ipolamide en tant qu'immunosuppresseurs pour le traitement de troubles immunologiques
WO2020166773A1 (fr) Composition pour dissoudre des réserves lipidiques locales, comprenant un extrait médicamenteux brut en tant que principe actif
CN112999227B (zh) 一种包含二-(苯并咪唑)-1,2,3-三唑衍生物的药物
KR102292069B1 (ko) 돌돔 인지질분해효소 유래의 항균 펩타이드를 유효성분으로 함유하는 암 치료용 약학적 조성물
KR102028519B1 (ko) 양식 어류 스쿠치카 항충 조성물
US20150258152A1 (en) Plant species that are an effective treatment for viral infections in animals and plants
KR101776932B1 (ko) 세드롤 또는 이의 유도체, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 약학적 조성물
WO2014014154A1 (fr) Composition de stabilisation d'antioxydant comprenant de l'alloféron
KR101828557B1 (ko) 세드롤 또는 이의 유도체, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 약학적 조성물
KR20050014453A (ko) 호노키올 또는 매그놀올을 함유하는 간 보호용 또는,간섬유화 및 간경화 치료용 또는 예방용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12878879

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12878879

Country of ref document: EP

Kind code of ref document: A1